Koninklijke Philips N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
10 feb 2010 - 08:30
Statutaire naam
Koninklijke Philips N.V.
Titel
Biocartis acquires Philips technology platform for automated DNA/RNA molecular diagnostic testing
Bericht
February 10, 2010
BIOCARTIS ACQUIRES PHILIPS TECHNOLOGY PLATFORM FOR AUTOMATED DNA/RNA MOLECULAR DIAGNOSTIC TESTING
Eindhoven, The Netherlands – Molecular diagnostics company Biocartis and Royal Philips Electronics (NYSE: PHG, AEX: PHI) today announced the signing of an agreement that will result in Biocartis acquiring Philips’ technology platform for rapid fully-automated DNA/RNA molecular diagnostic testing. The platform has been designed for applications in a wide range of patient sample testing, including oncology and infectious diseases. Financial details of this agreement were not disclosed.
Biocartis will develop and commercialize the platform, together with a menu of tests, through strategic partnerships and will finalize validation of the platform at its newly-established and wholly-owned Dutch subsidiary Biocartis BV. Biocartis BV is based on the High Tech Campus in Eindhoven, the Netherlands, where it will benefit from close access to the multi-disciplinary R&D facilities and services of Philips Corporate Technologies.
“This agreement is transformational for Biocartis as it accelerates our plans to bring innovative and cost-effective molecular diagnostic solutions that can turn personalized medicine into practice,” says Rudi Pauwels, CEO of Biocartis. “From our inception, we have been on a quest to integrate a clinical sample preparation and processing technology to complement our own developments. The platform developed by Philips clearly stood out as an impressive, integrated solution in terms of architecture choices, functionality, flexibility and bears the signature of a world-class engineering team.”
“We are extremely pleased that in Biocartis we have found a highly innovative and entrepreneurial partner that is committed to bringing a cutting-edge molecular diagnostics platform to market based on advanced technology developed by Philips,” says Gottfried Dutiné, Executive Vice President of Philips and Global Head of Markets & Innovation. “Bioca
Datum laatste update: 07 februari 2025